ShiraliAC, PerazellaMA, GettingerS: Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis68: 287–291, 2016PubMed
ShiraliAC, PerazellaMA, GettingerS: Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68: 287–291, 2016PubMed10.1053/j.ajkd.2016.02.057)| false
CortazarFB, KibbelaarZA, GlezermanIG, AbudayyehA, MamloukO, MotwaniSS, et al.: Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. J Am Soc Nephrol31: 435–446, 2020PubMed
KitchluA, FingrutW, Avila-CasadoC, ChanCT, CrumpM, HoggD, et al.: Nephrotic syndrome with cancer immunotherapies: A report of 2 cases. Am J Kidney Dis70: 581–585, 2017PubMed
KitchluA, FingrutW, Avila-CasadoC, ChanCT, CrumpM, HoggD, : Nephrotic syndrome with cancer immunotherapies: A report of 2 cases. Am J Kidney Dis 70: 581–585, 2017PubMed10.1053/j.ajkd.2017.04.026)| false
TakahashiN, TsujiK, TamiyaH, ShinoharaT, KurodaN, TakeuchiE: Goodpasture’s disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report. Lung Cancer122: 22–24, 2018PubMed
TakahashiN, TsujiK, TamiyaH, ShinoharaT, KurodaN, TakeuchiE: Goodpasture’s disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report. Lung Cancer 122: 22–24, 2018PubMed10.1016/j.lungcan.2018.05.015)| false
DaanenRA, MaasRJH, KoornstraRHT, SteenbergenEJ, van HerpenCML, WillemsenAECAB: Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: A case report. J Immunother40: 345–348, 2017PubMed
DaanenRA, MaasRJH, KoornstraRHT, SteenbergenEJ, van HerpenCML, WillemsenAECAB: Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: A case report. J Immunother 40: 345–348, 2017PubMed10.1097/CJI.0000000000000189)| false
LinJS, MamloukO, SelametU, TchakarovA, GlassWF, ShethRA, et al.: Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. OncoImmunology10: 1877415, 2021PubMed
MurakamiN, MulvaneyP, DaneshM, AbudayyehA, DiabA, Abdel-WahabN, et al.; Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium: A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int100: 196–205, 2021PubMed
MurakamiN, MulvaneyP, DaneshM, AbudayyehA, DiabA, Abdel-WahabN, ; Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium: A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int 100: 196–205, 2021PubMed10.1016/j.kint.2020.12.015)| false
MonteithBE, VennerCP, ReeceDE, KewAK, LalancetteM, GarlandJS, et al.: Drug-induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: A case series and review of the literature. Clin Lymphoma Myeloma Leuk20: e791–e800, 2020PubMed
MonteithBE, VennerCP, ReeceDE, KewAK, LalancetteM, GarlandJS, : Drug-induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: A case series and review of the literature. Clin Lymphoma Myeloma Leuk 20: e791–e800, 2020PubMed10.1016/j.clml.2020.04.014)| false
BallS, BeheraTR, AnwerF, ChakrabortyR: Risk of kidney toxicity with carfilzomib in multiple myeloma: A meta-analysis of randomized controlled trials. Ann Hematol99: 1265–1271, 2020PubMed
BallS, BeheraTR, AnwerF, ChakrabortyR: Risk of kidney toxicity with carfilzomib in multiple myeloma: A meta-analysis of randomized controlled trials. Ann Hematol 99: 1265–1271, 2020PubMed10.1007/s00277-020-04062-x)| false
ChenY, OoiM, LimSF, LinA, LeeJ, NagarajanC, et al.: Thrombotic microangiopathy during carfilzomib use: Case series in Singapore. Blood Cancer J6: e450, 2016PubMed
ChenY, OoiM, LimSF, LinA, LeeJ, NagarajanC, : Thrombotic microangiopathy during carfilzomib use: Case series in Singapore. Blood Cancer J 6: e450, 2016PubMed10.1038/bcj.2016.62)| false
Zibetti Dal MolinG, WestinSN, MsaouelP, GomesLM, DickensA, ColemanRL: Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer30: 89–93, 2020PubMed
Zibetti Dal MolinG, WestinSN, MsaouelP, GomesLM, DickensA, ColemanRL: Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer 30: 89–93, 2020PubMed10.1136/ijgc-2019-000714)| false
McCormickA, SwaislandH: In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib. Xenobiotica47: 903–915, 2017PubMed
McCormickA, SwaislandH: In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib. Xenobiotica 47: 903–915, 2017PubMed10.1080/00498254.2016.1241449)| false
BruinMAC, KorseCM, van WijnenB, de JongVMT, LinnSC, van TriestB, et al.: A real or apparent decrease in glomerular filtration rate in patients using olaparib?Eur J Clin Pharmacol77: 179–188, 2021PubMed
BruinMAC, KorseCM, van WijnenB, de JongVMT, LinnSC, van TriestB, : A real or apparent decrease in glomerular filtration rate in patients using olaparib?Eur J Clin Pharmacol 77: 179–188, 2021PubMed10.1007/s00228-020-03070-0)| false
ThillM, SchmidtM: Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol10: 1758835918793326, 2018PubMed
ThillM, SchmidtM: Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 10: 1758835918793326, 2018PubMed10.1177/1758835918793326)| false
OverkleeftEN, GoldschmedingR, van ReekumF, VoestEE, VerheulHM: Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol21: 184–185, 2010PubMed
OverkleeftEN, GoldschmedingR, van ReekumF, VoestEE, VerheulHM: Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 21: 184–185, 2010PubMed10.1093/annonc/mdp472)| false
IzzedineH, MangierM, OryV, ZhangSY, SendeyoK, BouachiK, et al.: Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int85: 457–470, 2014PubMed
IzzedineH, MangierM, OryV, ZhangSY, SendeyoK, BouachiK, : Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85: 457–470, 2014PubMed10.1038/ki.2013.344)| false
DelsanteM, Monroy-TrujilloJM, Carter-MonroeN, BallDW, RosenbergAZ: Lenvatinib-related renal microangiopathy: A case series [published online ahead of print May 6, 2021]. Virchows Arch10.1007/s00428-021-03114-5PubMed
DelsanteM, Monroy-TrujilloJM, Carter-MonroeN, BallDW, RosenbergAZ: Lenvatinib-related renal microangiopathy: A case series [published online ahead of print May 6, 2021]. Virchows Arch 10.1007/s00428-021-03114-5PubMed)| false
FurutoY, HashimotoH, NamikawaA, OutiH, TakahashiH, HoriutiH, et al.: Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: A case report. BMC Nephrol19: 273, 2018PubMed
NeelapuSS, LockeFL, BartlettNL, LekakisLJ, MiklosDB, JacobsonCA, et al.: Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med377: 2531–2544, 2017PubMed
NeelapuSS, LockeFL, BartlettNL, LekakisLJ, MiklosDB, JacobsonCA, : Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377: 2531–2544, 2017PubMed10.1056/NEJMoa1707447)| false
ParkJH, RivièreI, GonenM, WangX, SénéchalB, CurranKJ, et al.: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med378: 449–459, 2018PubMed
ParkJH, RivièreI, GonenM, WangX, SénéchalB, CurranKJ, : Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378: 449–459, 2018PubMed10.1056/NEJMoa1709919)| false
JainT, BarM, KansagraAJ, ChongEA, HashmiSK, NeelapuSS, et al.: Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: An expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant25: 2305–2321, 2019PubMed
JainT, BarM, KansagraAJ, ChongEA, HashmiSK, NeelapuSS, : Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: An expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25: 2305–2321, 2019PubMed10.1016/j.bbmt.2019.08.015)| false
JhaveriKD, RosnerMH: Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know. Clin J Am Soc Nephrol13: 796–798, 2018PubMed
JhaveriKD, RosnerMH: Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know. Clin J Am Soc Nephrol 13: 796–798, 2018PubMed10.2215/CJN.12871117)| false
Durlacher-BetzerK, HassanA, LeviR, AxelrodJ, SilverJ, Naveh-ManyT: Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int 94: 315–325, 2018PubMed10.1016/j.kint.2018.02.026)| false
DixonBN, DaleyRJ, BuieLW, HsuM, ParkJH, BrentjensRJ, et al.: Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells. Clin Nephrol93: 42–46, 2020PubMed
DixonBN, DaleyRJ, BuieLW, HsuM, ParkJH, BrentjensRJ, : Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells. Clin Nephrol 93: 42–46, 2020PubMed10.5414/CN109872)| false
SatwaniP, BavishiS, JinZ, JacobsonJS, BakerC, DuffyD, et al.: Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. Biol Blood Marrow Transplant17: 1472–1480, 2011PubMed
RichardsonPG, GruppSA, PagliucaA, KrishnanA, HoVT, CorbaciogluS: Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol6: 75–93, 2017PubMed
ChangsirikulchaiS, MyersonD, GuthrieKA, McDonaldGB, AlpersCE, HingoraniSR: Renal thrombotic microangiopathy after hematopoietic cell transplant: Role of GVHD in pathogenesis. Clin J Am Soc Nephrol4: 345–353, 2009PubMed
WanchooR, BayerRL, BassilC, JhaveriKD: Emerging concepts in hematopoietic stem cell transplantation-associated renal thrombotic microangiopathy and prospects for new treatments. Am J Kidney Dis72: 857–865, 2018PubMed
DvorakCC, HighamC, ShimanoKA: Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: A practical approach to diagnosis and management. Front Pediatr7: 133, 2019PubMed
DvorakCC, HighamC, ShimanoKA: Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: A practical approach to diagnosis and management. Front Pediatr 7: 133, 2019PubMed10.3389/fped.2019.00133)| false
UderzoC, BonanomiS, BuscaA, RenoldiM, FerrariP, IacobelliM, et al.: Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation82: 638–644, 2006PubMed
KraftS, BollingerN, BodenmannB, HeimD, BucherC, LengerkeC, et al.: High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transplant54: 540–548, 2019PubMed
KraftS, BollingerN, BodenmannB, HeimD, BucherC, LengerkeC, : High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transplant 54: 540–548, 2019PubMed10.1038/s41409-018-0293-3)| false
HainesHL, LaskinBL, GoebelJ, DaviesSM, YinHJ, LawrenceJ, et al.: Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant17: 1512–1519, 2011PubMed
HainesHL, LaskinBL, GoebelJ, DaviesSM, YinHJ, LawrenceJ, : Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17: 1512–1519, 2011PubMed10.1016/j.bbmt.2011.02.012)| false
ParkYH, LimJH, YiHG, LeeMH, KimCS: BK virus-hemorrhagic cystitis following allogeneic stem cell transplantation: Clinical characteristics and utility of leflunomide treatment. Turk J Haematol33: 223–230, 2016PubMed
GazievJ, PabaP, MianoR, GermaniS, SodaniP, BoveP, et al.: Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: A prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. Biol Blood Marrow Transplant16: 662–671, 2010PubMed
GazievJ, PabaP, MianoR, GermaniS, SodaniP, BoveP, : Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: A prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. Biol Blood Marrow Transplant 16: 662–671, 2010PubMed10.1016/j.bbmt.2009.12.009)| false
NesselhaufN, StruttJ, BastaniB: Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. J Nephropathol5: 34–37, 2016PubMed
NesselhaufN, StruttJ, BastaniB: Evaluation of leflunomide for the treatment of BK viremia and biopsy proven BK nephropathy; a single center experience. J Nephropathol 5: 34–37, 2016PubMed10.15171/jnp.2016.06)| false
PhilippeM, RanchonF, GilisL, SchwiertzV, VantardN, AderF, et al.: Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant22: 723–730, 2016PubMed
Beyar-KatzO, DavilaEK, ZuckermanT, FinemanR, HaddadN, OkashaD, et al.: Adult nephrotic syndrome after hematopoietic stem cell transplantation: Renal pathology is the best predictor of response to therapy. Biol Blood Marrow Transplant22: 975–981, 2016PubMed
HingoraniS, PaoE, StevensonP, SchochG, LaskinBL, GooleyT, et al.: Changes in glomerular filtration rate and impact on long-term survival among adults after hematopoietic cell transplantation: A prospective cohort study. Clin J Am Soc Nephrol13: 866–873, 2018PubMed
GlezermanIG, DevlinS, MaloyM, BuiM, JaimesEA, GiraltSA, et al.: Long term renal survival in patients undergoing T-cell depleted versus conventional hematopoietic stem cell transplants. Bone Marrow Transplant52: 733–738, 2017PubMed
JacobyE, ChenA, LoebDM, GamperCJ, ZambidisE, LlosaNJ, et al.: Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant22: 112–118, 2016PubMed
JacobyE, ChenA, LoebDM, GamperCJ, ZambidisE, LlosaNJ, : Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant 22: 112–118, 2016PubMed10.1016/j.bbmt.2015.08.034)| false
HingoraniS, GooleyT, PaoE, SandmaierB, McDonaldG: Urinary cytokines after HCT: Evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease. Bone Marrow Transplant49: 403–409, 2014PubMed
HingoraniS, GooleyT, PaoE, SandmaierB, McDonaldG: Urinary cytokines after HCT: Evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease. Bone Marrow Transplant 49: 403–409, 2014PubMed10.1038/bmt.2013.197)| false
